Moderna shares declined on May 13 as speculative interest in a hantavirus vaccine faded.
Health officials reassured investors that a major hantavirus outbreak remains unlikely. This guidance prompted traders to unwind positions built on recent localized outbreak news.
Market focus is returning to the company’s long-term fundamentals and product pipeline. The stock fell despite TIME naming Moderna the most impactful company of 2026.